Form 8-K - Current report:
SEC Accession No. 0001193125-22-153601
Filing Date
2022-05-18
Accepted
2022-05-18 08:05:57
Documents
14
Period of Report
2022-05-16
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d314508d8k.htm   iXBRL 8-K 28457
2 EX-99.1 d314508dex991.htm EX-99.1 10779
6 GRAPHIC g314508g0518044707310.jpg GRAPHIC 4500
  Complete submission text file 0001193125-22-153601.txt   176351

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA pstx-20220516.xsd EX-101.SCH 2846
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE pstx-20220516_lab.xml EX-101.LAB 18739
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE pstx-20220516_pre.xml EX-101.PRE 11701
8 EXTRACTED XBRL INSTANCE DOCUMENT d314508d8k_htm.xml XML 3478
Mailing Address 9390 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 9390 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121 858-779-3100
Poseida Therapeutics, Inc. (Filer) CIK: 0001661460 (see all company filings)

IRS No.: 472846548 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39376 | Film No.: 22937110
SIC: 2836 Biological Products, (No Diagnostic Substances)